# Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

> **NCT02259595** · PHASE1 · COMPLETED · sponsor: **Otologic Pharmaceutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Hearing Loss
- Sensorineural Hearing Loss
- Noise-Induced Hearing Loss

## Interventions

- **DRUG:** HPN-07
- **DRUG:** NAC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02259595
- **Lead sponsor:** Otologic Pharmaceutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-01
- **Final completion:** 2015-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259595, "Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02259595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*